Mariner’s Ovid Therapeutics OVID Stock Holding History

Mariner’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,500	Closed	-$35K	–	2896
2023 Q1	$35K	Sell	13,500 -1,000	-7%	-$2.37K	﹤0.01%	2686
2022 Q4	$27K	Sell	14,500 -4,500	-24%	-$7.67K	﹤0.01%	2665
2022 Q3	$35K	Buy	+19,000	New	+$39.8K	﹤0.01%	2347

Other funds holding OVID

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mariner's OVID Position: Q2 2023 in Review

Mariner sold out of Ovid Therapeutics (OVID) in Q2 2023, closing a stake of 13,500 shares — an estimated $35K sold.

Mariner first reported a position in OVID in Q3 2022 and held it in 3 quarters. The position peaked at $35K in Q1 2023. 69 funds tracked by Wall St. Rank hold OVID as of Q2 2023.

Mariner reported no remaining Ovid Therapeutics position as of Q2 2023 after selling out during the quarter.
Mariner sold 13,500 Ovid Therapeutics shares in Q2 2023, an estimated $35K.
Mariner first reported a position in Ovid Therapeutics in Q3 2022 and held it in 3 quarters.
Mariner's Ovid Therapeutics position peaked at $35K in Q1 2023.
69 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2023.

Based on Mariner's 13F filing for Q2 2023, filed 11 Aug 2023.